503A vs 503B pharmacy: what it means for your medication

503A and 503B are two sections of the same federal law that govern pharmacy compounding. A 503A pharmacy is the traditional kind: it prepares medication for individual patients against a prescription, and it is regulated primarily by state boards of pharmacy. A 503B facility is an outsourcing facility: it registers with the FDA, is inspected by the FDA, and must follow cGMP (current Good Manufacturing Practice), the same manufacturing standard used by commercial drug makers.

Both are legal. Both are legitimate. Neither produces an FDA-approved finished drug, because compounded medications are not FDA-approved. The meaningful difference is the level of manufacturing oversight, and a 503B adds more of it.

A 503A is what most people picture when they hear “compounding pharmacy.” It compounds medication for a specific patient, in response to a prescription from that patient's provider. These pharmacies are licensed and regulated primarily by state boards of pharmacy, with the FDA in an oversight role. They are not required to follow full cGMP, the manufacturing standard that governs large-scale drug production.

That is not a knock on 503A pharmacies. Patient-specific compounding is exactly what they are built for, and dispensing on a real prescription is the right model for a personal, increasing-dose plan like tirzepatide.

A 503B is an outsourcing facility. It registers directly with the FDA, is inspected by the FDA on a risk-based schedule, and must comply with cGMP. Because of that higher bar, a 503B can produce larger batches, including without a patient-specific prescription.

In practical terms, a 503B adds manufacturing-grade quality controls: documented processes, testing, and FDA inspection of the facility itself. It still does not make an FDA-approved finished drug, but the medication is produced under the same manufacturing standard as commercial drug makers.

Most brands hide this part. Crossing puts it in writing, because naming the pharmacies is the whole point of buying from a transparent provider.

• Manufactured by BPI Labs (503B). Your tirzepatide is made by BPI Labs, an FDA-registered 503B outsourcing facility in Largo, FL, held to cGMP, the same manufacturing standard as commercial drug makers. That is the manufacturing-grade quality control a 503B is built to provide.
• Dispensed by The Pharmacy Hub (503A).Your medication is dispensed by The Pharmacy Hub, a licensed 503A pharmacy, on your provider's prescription. That is the patient-specific, prescription-based model that fits a personal increasing-dose plan.
• Compounded with vitamin B6. The formulation includes vitamin B6.

So you get the best of both: a 503B facility making the medication under cGMP, and a 503A pharmacy dispensing it to you on a real prescription. You can read more about the compounded tirzepatide product, see how we stack up on our compare page, or look at exactly where every dollar goes.

Naming the pharmacies is part of a larger habit: telling you exactly what you are getting and what it costs. Crossing is one flat $149 a month, every dose, all in. That covers the medication, provider review, your increasing-dose plan, and shipping, with no re-order jump and no dose-based upcharge. If you want the cash-price context, see how much tirzepatide costs across the market.